AU2019333310B8 - Salts and crystal forms of GABAA positive allosteric modulator - Google Patents

Salts and crystal forms of GABAA positive allosteric modulator Download PDF

Info

Publication number
AU2019333310B8
AU2019333310B8 AU2019333310A AU2019333310A AU2019333310B8 AU 2019333310 B8 AU2019333310 B8 AU 2019333310B8 AU 2019333310 A AU2019333310 A AU 2019333310A AU 2019333310 A AU2019333310 A AU 2019333310A AU 2019333310 B8 AU2019333310 B8 AU 2019333310B8
Authority
AU
Australia
Prior art keywords
compound
exhibits
xrpd
peaks
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019333310A
Other languages
English (en)
Other versions
AU2019333310B2 (en
AU2019333310A1 (en
AU2019333310A8 (en
Inventor
Gabriel Martinez Botella
Paul A. Laskar
Nelson B. Olivier
Kiran Reddy
Magnus Ronn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of AU2019333310A1 publication Critical patent/AU2019333310A1/en
Application granted granted Critical
Publication of AU2019333310B2 publication Critical patent/AU2019333310B2/en
Publication of AU2019333310B8 publication Critical patent/AU2019333310B8/en
Publication of AU2019333310A8 publication Critical patent/AU2019333310A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
AU2019333310A 2018-08-31 2019-08-30 Salts and crystal forms of GABAA positive allosteric modulator Active AU2019333310B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725805P 2018-08-31 2018-08-31
US62/725,805 2018-08-31
US16/517,369 US10562930B1 (en) 2018-08-31 2019-07-19 Salts and crystal forms of GABAA positive allosteric modulator
US16/517,369 2019-07-19
PCT/US2019/049103 WO2020047434A1 (en) 2018-08-31 2019-08-30 Salts and crystal forms of gabaa positive allosteric modulator

Publications (4)

Publication Number Publication Date
AU2019333310A1 AU2019333310A1 (en) 2021-04-08
AU2019333310B2 AU2019333310B2 (en) 2024-11-21
AU2019333310B8 true AU2019333310B8 (en) 2025-04-17
AU2019333310A8 AU2019333310A8 (en) 2025-04-17

Family

ID=69528249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019333310A Active AU2019333310B8 (en) 2018-08-31 2019-08-30 Salts and crystal forms of GABAA positive allosteric modulator

Country Status (13)

Country Link
US (4) US10562930B1 (enExample)
EP (2) EP4458357B1 (enExample)
JP (3) JP7199739B2 (enExample)
KR (1) KR102845326B1 (enExample)
CN (2) CN113473991B (enExample)
AU (1) AU2019333310B8 (enExample)
BR (1) BR112021003727A2 (enExample)
CA (1) CA3111193A1 (enExample)
IL (1) IL281143B2 (enExample)
MA (1) MA50921A (enExample)
MX (1) MX2021002382A (enExample)
TW (2) TWI823999B (enExample)
WO (1) WO2020047434A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
WO2022178000A1 (en) * 2021-02-18 2022-08-25 Praxis Precision Medicines, Inc. Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof
US20240207366A1 (en) 2021-04-27 2024-06-27 Kyungpook National University Industry-Academic Cooperation Foundation Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
US20250170148A1 (en) * 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
EP4514357A4 (en) * 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
UA73736C2 (en) 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
CN1688288A (zh) * 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2005007600A2 (en) 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
AU2004265101B2 (en) 2003-08-14 2009-06-11 F. Hoffmann-La Roche Ag Gabanergic modulators
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
ES2635358T3 (es) * 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
WO2011104637A2 (en) * 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
KR20140009244A (ko) * 2010-11-11 2014-01-22 애크런 몰레큘스 게엠베하 통증 치료용 화합물 및 방법
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
EP3308785A3 (en) 2013-07-24 2018-07-18 Commissariat à l'Energie Atomique et aux Energies Alternatives Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
KR102516745B1 (ko) * 2014-08-01 2023-03-31 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
SG11202004329TA (en) 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
JP2022514510A (ja) 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2021010744A (es) 2019-03-04 2022-01-18 Praxis Prec Medicines Inc Metodos para el tratamiento de la perimenopausia y la menopausia.
WO2020185710A1 (en) 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor
US20220265666A1 (en) 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
AU2020358002A1 (en) 2019-10-02 2022-04-21 Praxis Precision Medicines, Inc. Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists
WO2021168106A1 (en) 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
WO2022006541A1 (en) 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
US20230416300A1 (en) 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2022178000A1 (en) 2021-02-18 2022-08-25 Praxis Precision Medicines, Inc. Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof
CN117715641A (zh) 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
WO2023159094A2 (en) 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
EP4514357A4 (en) 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Also Published As

Publication number Publication date
CN113473991B (zh) 2025-12-26
EP4458357A2 (en) 2024-11-06
IL281143B1 (en) 2024-12-01
TWI850138B (zh) 2024-07-21
JP2025020120A (ja) 2025-02-12
JP2021504297A (ja) 2021-02-15
US10562930B1 (en) 2020-02-18
CA3111193A1 (en) 2020-03-05
CN113473991A (zh) 2021-10-01
AU2019333310B2 (en) 2024-11-21
AU2019333310A1 (en) 2021-04-08
US20220024967A1 (en) 2022-01-27
US20200255471A1 (en) 2020-08-13
EP4458357B1 (en) 2026-08-19
EP3710465A4 (en) 2020-09-23
US12404297B2 (en) 2025-09-02
KR102845326B1 (ko) 2025-08-12
US10927141B2 (en) 2021-02-23
EP3710465B1 (en) 2024-08-14
CN122103232A (zh) 2026-05-29
KR20210054546A (ko) 2021-05-13
TW202408461A (zh) 2024-03-01
US20240140985A1 (en) 2024-05-02
TWI823999B (zh) 2023-12-01
EP3710465A1 (en) 2020-09-23
MX2021002382A (es) 2021-08-11
WO2020047434A1 (en) 2020-03-05
TW202024108A (zh) 2020-07-01
US20200071350A1 (en) 2020-03-05
AU2019333310A8 (en) 2025-04-17
JP7199739B2 (ja) 2023-01-06
IL281143A (en) 2021-04-29
IL281143B2 (en) 2025-04-01
BR112021003727A2 (pt) 2021-05-25
MA50921A (fr) 2020-09-23
JP2023036708A (ja) 2023-03-14
EP4458357A3 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
AU2019333310B2 (en) Salts and crystal forms of GABAA positive allosteric modulator
NO326148B1 (no) Tartratsalter av 5,8,14-triazatetracyklo (10.3.1.0<O>2,11</O>.0<O>4.9</O>)-heksadeka-2 (11),3,5,7,9-pentaen, samt anvendelse derav og farmasoytisk blanding derav
US11434226B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
EP3798224B1 (en) Solid state forms of ixazomib citrate
HK40118203A (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178B (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178A (en) Salts and crystal forms of gabaa positive allosteric modulator
BR112019019102A2 (pt) sal de ácido, composto, processo para preparar um sal de ácido de pivalato, composição farmacêutica, método para tratar uma doença que responde à inibição de atividade de transcriptase reversa de nucleotídeo, e, uso de um sal de ácido.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 58 , NO 46 , PAGE(S) 6740 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PRAXIS PRECISION MEDICINES, INC., APPLICATION NO. 2019333310, UNDER INID (54) CORRECT THE TITLE TO READ SALTS AND CRYSTAL FORMS OF GABAA POSITIVE ALLOSTERIC MODULATOR

Free format text: IN VOL 35 , NO 14 , PAGE(S) 3250 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PRAXIS PRECISION MEDICINES, INC., APPLICATION NO. 2019333310, UNDER INID (54) CORRECT THE TITLE TO READ SALTS AND CRYSTAL FORMS OF GABAA POSITIVE ALLOSTERIC MODULATOR